Related Experiment Video
Updated: Apr 18, 2026
Enhanced Gene Delivery and Expression using Intraosseous Injection of Chitosan Nanoparticles Encapsulated Adenine Base Editor Plasmids
Published on: May 16, 2025
Triazine-modified dendrimer for efficient TRAIL gene therapy in osteosarcoma
Yu Wang1, Lei Li2, Naimin Shao3
1Department of Orthopedic Oncology, Changzheng Hospital, Second Military Medical University, Shanghai 200003, PR China; Department of Spine Surgery, First Affiliated Hospital of Wenzhou Medical University, Zhejiang 325000, PR China.
Abstract:
Osteosarcoma is a high-grade malignant bone tumor that usually develops in the teenagers. Despite improvement in therapy, the five-year survival rate is poor for patients not responding to treatment or with metastases. Tumor necrosis factor (TNF) related apoptosis inducing ligand (TRAIL) gene therapy is a new strategy in the treatment of cancers, however, the lack of efficient and low toxic vectors remains the major obstacle in TRAIL gene therapy. In this study, a triazine-modified dendrimer G5-DAT66 was synthesized and used as a vector for TRAIL gene therapy in vitro and in vivo. The material shows much higher transfection efficacy on osteosarcoma MG-63 cell line than commercial transfection reagents such as Lipofectamine 2000 and SuperFect. It effectively induces apoptosis in MG-63 cells and three-dimensional MG-63 cell cultures when delivering a TRAIL plasmid. In vivo studies further prove that G5-DAT66 efficiently transfects TRAIL plasmid in tumors and inhibits tumor growth in osteosarcoma-bearing mice. These results suggest that triazine-modified dendrimer has promising potential for TRAIL gene therapy in osteosarcoma.
Insights
A novel triazine-modified dendrimer, G5-DAT66, shows high efficacy in delivering the Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand (TRAIL) gene. This dendrimer effectively treats osteosarcoma by inducing cancer cell death and inhibiting tumor growth in vivo.
Area of Science:
- Biomaterials Science
- Cancer Gene Therapy
- Nanotechnology
Background:
- Osteosarcoma is a prevalent bone cancer with poor survival rates for non-responsive or metastatic cases.
- Current treatments face challenges, necessitating novel therapeutic strategies.
- Gene therapy using Tumor Necrosis Factor (TNF)-related apoptosis inducing ligand (TRAIL) shows promise but is hindered by inefficient and toxic delivery vectors.
Purpose of the Study:
- To synthesize and evaluate a novel triazine-modified dendrimer (G5-DAT66) as a vector for TRAIL gene therapy in osteosarcoma.
- To assess the in vitro and in vivo transfection efficiency and therapeutic efficacy of G5-DAT66 for osteosarcoma treatment.
Main Methods:
- Synthesis of a triazine-modified dendrimer G5-DAT66.
- In vitro evaluation of transfection efficacy against commercial reagents (Lipofectamine 2000, SuperFect) in MG-63 osteosarcoma cells.
- Assessment of apoptosis induction in MG-63 cells and 3D cultures.
- In vivo studies in osteosarcoma-bearing mice to evaluate tumor transfection and growth inhibition.
Main Results:
- G5-DAT66 demonstrated superior transfection efficacy compared to Lipofectamine 2000 and SuperFect in MG-63 cells.
- The dendrimer effectively induced apoptosis in osteosarcoma cells in vitro.
- In vivo studies confirmed efficient TRAIL plasmid transfection in tumors and significant inhibition of tumor growth.
Conclusions:
- Triazine-modified dendrimer G5-DAT66 is a highly effective and low-toxic vector for TRAIL gene therapy.
- G5-DAT66 shows significant potential for the treatment of osteosarcoma.
- This nanocarrier offers a promising platform for advancing cancer gene therapy strategies.
More Related Videos
Related Concept Videos
00:59Gene Therapy
00:59Gene Therapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...